Peyona (caffeine citrate) 20 mg/ml solution for infusion and oral solution
- Name:
Peyona (caffeine citrate) 20 mg/ml solution for infusion and oral solution
- Company:
Chiesi Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 24/01/19
(Click to Download)Click on this link to Download PDF directly
Chiesi Limited
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name Bramitob Nebuliser Solution | Active Ingredients Tobramycin |
| Medicine Name CUROSURF 120mg | Active Ingredients phospholipid fraction from porcine lung (poractant alfa) |
| Medicine Name CUROSURF 240mg | Active Ingredients phospholipid fraction from porcine lung (poractant alfa) |
| Medicine Name Envarsus 0.75mg; 1mg; 4mg prolonged-release tablet | Active Ingredients Tacrolimus Monohydrate |
| Medicine Name Peyona (caffeine citrate) 20 mg/ml solution for infusion and oral solution | Active Ingredients Caffeine citrate |
| Medicine Name Procysbi 25mg / 75mg gastro-resistant hard capsules | Active Ingredients Cysteamine (as mercaptamine bitartrate) |
| Medicine Name Quinsair 240 mg nebuliser solution | Active Ingredients Levofloxacin hemihydrate |
| Medicine Name Zileze 3.75mg Film Coated Tablets | Active Ingredients Zopiclone |
| Medicine Name Zileze 7.5mg Film Coated Tablets | Active Ingredients Zopiclone |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 24 January 2019 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 24 January 2019 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Changed from 09/2017 to November 2018
Updated on 8 May 2018 Ed-HCP
Reasons for updating
- Add New Doc
Free text change information supplied by the pharmaceutical company
Information on the safe use of Peyona (caffeine citrate) 20mg/ml solution for infusion and oral solution
Updated on 8 May 2018 Ed-HCP
Reasons for updating
- Add New Doc
Free text change information supplied by the pharmaceutical company
Peyona (caffeine citrate) 20 mg/ml Solution for Infusion and Oral Solution Laminated Card
Updated on 23 October 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 23 October 2017 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
A Type IA Variation was submitted to change the name of product manufacturer & batch release site registered on the licence.
Section 10 change of date of revision from August 2017 to October 2017
Updated on 19 October 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 19 October 2017 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 18 August 2017 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
10. DATE OF REVISION OF THE TEXT February 2015 changed to August 2017
Updated on 18 August 2017 PIL
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 1 June 2015 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - MA number
- Change to section 10 - Date of revision of the text
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 – Hepatic and renal impairment – The safety of caffeine citrate in patients with renal impairment has not been established – has been removed
Section 4.4 – Renal and hepatic impairment - In a post-authorisation safety study, the frequency of adverse reactions in a small number of very premature infants with renal/hepatic impairment appeared to be higher as compared to premature infants without organ impairment – has been added
(see sections 4.2,4.8 and 5.2) has been amended to add 4.8
Section 4.8 – and - had been removed
Convulsion, arrhythmia, metabolism and nutrition disorders such as hyperglycaemia, and obtained from a post-authorisation safety study – has been added
Changes to the side effects table include – Hyperglycaemia , common
Hyperglycaemia changed to Hypoglycaemia
Convulsion, Uncommon
Convulsion removed from frequency unknown
Tachycardia , common
Arrhythmia, Uncommon
Tachycardia also associated with – removed
New section added - Other special populations
In a post-authorisation safety study on 506 preterm infants treated with Peyona, safety data have been collected in 31 very premature infants with renal/hepatic impairment. Adverse reactions appeared to be more frequent in this subgroup with organ impairment than in other observed infants without organ impairment. Cardiac disorders (tachycardia, including one single case of arrhythmia) were mostly reported.
Section - Reporting of suspected adverse reactions
the national reporting system listed in Appendix V has been replaced by UK: Yellow Card Scheme at www.mhra.gov.uk/yellowcard .
ROI: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax:
+353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie
Section 6.5 – Nature and contents of container - Type I clear glass 3 ml ampoule – removed
Section 8 – Marketing Authorisation Number(s) - 1 ml ampoules EU/1/09/528/001 3 ml ampoules – removed
Section 10 - Date of revision of the Text – February 2015
Updated on 22 May 2015 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 12 February 2015 PIL
Reasons for updating
- Improved electronic presentation
Updated on 25 March 2014 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 21 March 2014 PIL
Reasons for updating
- Change to side-effects
- Change to name of manufacturer
- Introduction of new pack/pack size
Updated on 16 October 2013 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 16 October 2013 PIL
Reasons for updating
- Change of distributor details
Updated on 15 May 2012 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 14 May 2012 PIL
Reasons for updating
- New PIL for new product
Peyona (caffeine citrate) 20 mg/ml SolutionRisk Minimisation Materials
(Click to Download)Peyona (caffeine citrate) 20mg/ml solution LetterRisk Minimisation Materials
(Click to Download)
Educational Materials for Medicines
Educational Materials for Medicines